New drug aimed at making risky sickle cell transplants safer
NCT ID NCT06078696
Summary
This study tested whether adding a drug called siplizumab to a stem cell transplant could make the procedure safer and more effective for adults with severe sickle cell disease. The main goal was to see if the drug could prevent the donor cells from being rejected (graft failure) and reduce a dangerous complication where donor cells attack the patient's body. The study was stopped early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA, SICKLE CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.